Your browser doesn't support javascript.
loading
Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.
Lee, Cathryn T; Strek, Mary E; Adegunsoye, Ayodeji; Wong, Alyson W; Assayag, Deborah; Cox, Gerard; Fell, Charlene D; Fisher, Jolene H; Gershon, Andrea S; Halayko, Andrew J; Hambly, Nathan; Khalil, Nasreen; Kolb, Martin; Lok, Stacey D; Manganas, Hélène; Marcoux, Veronica; Morisset, Julie; Sadatsafavi, Mohsen; Shapera, Shane; To, Teresa; Wilcox, Pearce; Ryerson, Christopher J; Johannson, Kerri A.
Afiliação
  • Lee CT; Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.
  • Strek ME; Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.
  • Adegunsoye A; Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.
  • Wong AW; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Assayag D; Center for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Cox G; Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Fell CD; Medicine (Respirology), McMaster University, Hamilton, Ontario, Canada.
  • Fisher JH; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Gershon AS; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Halayko AJ; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Hambly N; Physiology/Internal Medicine (Respirology), University of Manitoba, Winnipeg, Manitoba, Canada.
  • Khalil N; Medicine (Respirology), McMaster University, Hamilton, Ontario, Canada.
  • Kolb M; Division of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Lok SD; Medicine (Respirology), McMaster University, Hamilton, Ontario, Canada.
  • Manganas H; Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Marcoux V; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Morisset J; Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Sadatsafavi M; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Shapera S; Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
  • To T; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Wilcox P; Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Ryerson CJ; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Johannson KA; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Respirology ; 27(8): 635-644, 2022 08.
Article em En | MEDLINE | ID: mdl-35512793
ABSTRACT
BACKGROUND AND

OBJECTIVE:

Inhalational exposures are a known cause of interstitial lung disease (ILD), but little is understood about their prevalence across ILD subtypes and their relationship with pulmonary function and survival.

METHODS:

Patients with fibrotic ILD were identified from the multicentre Canadian Registry for Pulmonary Fibrosis. Patients completed questionnaires regarding ILD-related occupational and environmental exposures. The relationship between exposures and the outcomes of baseline age, gender, family history, pulmonary function and survival was analysed using linear and logistic regression models, linear mixed-effect regression models and survival analysis using multivariable Cox proportional hazards along with the log-rank test.

RESULTS:

There were 3820 patients included in this study, with 2385 (62%) having ILD-related inhalational exposure. Exposed patients were younger, particularly in the idiopathic pulmonary fibrosis subgroup. Inhalational exposure was associated with male gender (adjusted OR 1.46, 95% CI 1.28-1.68, p < 0.001) and family history of pulmonary fibrosis (adjusted OR 1.73, 95% CI 1.40-2.15, p < 0.001). Patients with any inhalational exposure had improved transplant-free survival (hazard ratio 0.81, 95% CI 0.71-0.92, p = 0.001); this effect persisted across diagnostic subtypes. The relationship between exposures and annual change in forced vital capacity varied by ILD subtype.

CONCLUSION:

Patients with fibrotic ILD report high prevalence of inhalational exposures across ILD subtypes. These exposures were associated with younger age at diagnosis, male gender and family history of pulmonary fibrosis. Identification of an inhalational exposure was associated with a survival benefit. These findings suggest that inhaled exposures may impact clinical outcomes in patients with ILD, and future work should characterize the mechanisms underlying these relationships.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Respirology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Respirology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos